Krsnaa Diagnostics Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹175Cr
- +10.1% YoY
- +6.1% QoQ
- Net profit
- ₹21Cr
- +16.7% YoY
- −4.5% QoQ
- Margin
- 31%
- +4 pp YoY
- +2 pp QoQ
The short version
Growth momentum expected to resume in FY '26 with aspirations to surpass previous levels. FY25 revenue grew 16% YoY to INR 7,172 million; EBITDA rose 34% to INR 1,958 million with a 27% margin; net profit up 37% to INR 776 million with 11% margin.
From Krsnaa Diagnost.'s Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Growth momentum expected to resume in FY '26 with aspirations to surpass previous levels.
- Radiology and pathology volumes are increasing, with a balanced 50:50 revenue mix.
- Younger centers, especially in radiology, projected to mature and contribute significantly from FY '26 onwards.
- Retail business (B2C) anticipated to contribute 5-8% of revenue in FY '26, growing from ~3.5% in Q4 FY '25.
- Retail touch points are expanding rapidly (nearly 4x growth in 1 year), supporting growth.
- Overall revenue growth target is around 16%+ for FY '26, with expectations to outperform the industry.
2 more points from Krsnaa Diagnost.'s call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Krsnaa Diagnost. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- For FY '26, planned investments are in the range of INR 100 to 150 crores.
- Due to adoption of an asset-light model, actual cash outflow is expected to be significantly less than INR 100 crores.
- Investments will focus on implementing sizable tenders won at favorable rates.
- Capex mainly targets new radiology centers in Madhya Pradesh, Maharashtra, Delhi, and pathology collection centers in Assam and Orissa.
- Collection centers require minimal capex, primarily for basic infrastructure like refrigerators and basic test equipment.
- Strategic partnerships involve deferred equipment payments with 7% annual interest to support infrastructure.
2 more points from Krsnaa Diagnost.'s call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Krsnaa Diagnost. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company continues to win tenders and deepen its presence in Tier 2 and Tier 3 cities.
- There is a strong forward visibility supported by the order book and upcoming project pipeline.
- Various sizable tenders already won are expected to require investments of about INR 100-150 crores in FY '26.
2 more points from Krsnaa Diagnost.'s call on order book
Create a free account to keep reading this call
Krsnaa Diagnost. — Quarterly revenue & net profit
Krsnaa Diagnost. Q4 FY25 results — key figures
| ₹ Cr | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 175 | 159 | +10.1% | 165 | +6.1% |
| Operating profit (EBITDA) | 53 | 43 | +23.3% | 48 | +10.4% |
| Operating margin | 31% | 27% | +4 pp | 29% | +2 pp |
| Profit before tax | 29 | 22 | +31.8% | 28 | +3.6% |
| Net profit (PAT) | 21 | 18 | +16.7% | 22 | -4.5% |
| EPS (₹) | 6.53 | 5.70 | +14.6% | 6.69 | -2.4% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹240 Cr, net profit ₹25 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Krsnaa Diagnostics's management said in earlier quarters
Others in Healthcare Services this season
- 3B Blackbio (Q4 FY25)
UK subsidiary (TRUPCR Europe Limited) revenue FY 2024-25: GBP 1,287,580, a 94% increase over FY 2023-24 GBP 664,059. Key concall takeaways from 3B Blackbio DX…
- Apollo Hospitals (Q4 FY25)
. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Shalby (Q4 FY25)
Implant business is in high-growth mode: 4x growth in Indonesia, 35-40% growth in U.S., and 2.5x growth in India reported last year. Key concall takeaways from…
- Narayana Hrudaya (Q4 FY25)
Capex is split between regular maintenance/replacement (~INR 300 crores) and new greenfield/brownfield capacity (~INR 450 crores) with some variability based…
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Krsnaa Diagnost. and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Krsnaa Diagnost. Q4 FY25 results?
Growth momentum expected to resume in FY '26 with aspirations to surpass previous levels. FY25 revenue grew 16% YoY to INR 7,172 million; EBITDA rose 34% to INR 1,958 million with a 27% margin; net profit up 37% to INR 776 million with 11% margin.
What is Krsnaa Diagnost. share price analysis?
Krsnaa Diagnost. currently shows a neutral. The stock trades at a P/E of 19.1 with a market cap of ₹1,866 Cr. Investors should review the full earnings analysis for detailed insights.
Is Krsnaa Diagnost. planning capital expenditure?
For FY '26, planned investments are in the range of INR 100 to 150 crores.
Keep Krsnaa Diagnost. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
